Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress

Oncotarget

Volumn 5, Issue 1, 2014, Pages 298-308

  Lin, Yu Chin ^a,b,c   Wu, Meng Hsuan ^a   Wei, Tzu Tang ^a   Lin, Yun Chieh ^a   Huang, Wen Chih ^c   Huang, Liang Yu ^a   Lin, Yi Ting ^a   Chen, Ching Chow ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

AMPK; Dasatinib; EGFR; ER stress; PDK4

Indexed keywords

ADENOSINE TRIPHOSPHATE; CBL PROTEIN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; PYRUVATE DEHYDROGENASE KINASE 4; ANTINEOPLASTIC AGENT; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PROTEIN DEGRADATION; UPREGULATION; ANIMAL; CARCINOMA, SQUAMOUS CELL; CELL GROWTH; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; HEAD AND NECK NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG SYNERGISM; ENDOPLASMIC RETICULUM STRESS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; METFORMIN; MICE; MICE, NUDE; PYRIMIDINES; THIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893841404     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Kaufman RJ. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev. 1999; 13(10):1211-1233.
2. Szegezdi E, Logue SE, Gorman AM and Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 2006; 7(9):880-885.
3. Zhao L and Ackerman SL. Endoplasmic reticulum stress in health and disease. Curr Opin Cell Biol. 2006; 18(4):444-452.
4. Wang G, Yang ZQ and Zhang K. Endoplasmic reticulum stress response in cancer: molecular mechanism and therapeutic potential. Am J Transl Res. 2010; 2(1):65-74.
5. Sanders MJ, Grondin PO, Hegarty BD, Snowden MA and Carling D. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J. 2007; 403(1):139-148.
6. Ruderman N and Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov. 2004; 3(4):340-351.
7. Calle EE, Rodriguez C, Walker-Thurmond K and Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348(17):1625-1638.
8. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330(7503):1304-1305.
9. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD and Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009; 32(9):1620-1625.
10. Kuznetsov JN, Leclerc GJ, Leclerc GM and Barredo JC. AMPK and Akt determine apoptotic cell death following perturbations of one-carbon metabolism by regulating ER stress in acute lymphoblastic leukemia. Mol Cancer Ther. 2011; 10(3):437-447.
11. Liu Yang HS, Robin L. Davisson and Ling Qi. Phenformin Activates Unfolded Protein Response in an AMP-Activated Protein Kinase (AMPK)-Dependent Manner. J Biol Chem 2013.
12. Psyrri A, Gouveris P and Vermorken JB. Human papillomavirus-related head and neck tumors: clinical and research implication. Curr Opin Oncol. 2009; 21(3):201-205.
13. Hynes NE and Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5(5):341-354.
14. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK and Milas L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002; 62(24):7350-7356.
15. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359(11):1116-1127.
16. Ahmed SM and Cohen EE. Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors. Curr Cancer Drug Targets. 2007; 7(7):666-673.
17. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP and Sawyers CL. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354(24):2531-2541.
18. Bromann PA, Korkaya H and Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene. 2004; 23(48):7957-7968.
19. Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT and Papadimitrakopoulou VA. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer. 2011; 117(10):2112-2119.
20. Lin YC, Wu MH, Wei TT, Chuang SH, Chen KF, Cheng AL and Chen CC. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells. Neoplasia. 2012; 14(6):463-475.
21. Authier F, Metioui M, Bell AW and Mort JS. Negative regulation of epidermal growth factor signaling by selective proteolytic mechanisms in the endosome mediated by cathepsin B. J Biol Chem. 1999; 274(47):33723-33731.
22. Yang PM, Liu YL, Lin YC, Shun CT, Wu MS and Chen CC. Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res. 2010; 70(19):7699-7709.
23. Ferreira LM, Hebrant A and Dumont JE. Metabolic reprogramming of the tumor. Oncogene. 2012; 31(36):3999-4011.
24. McFate T, Mohyeldin A, Lu H, Thakar J, Henriques J, Halim ND, Wu H, Schell MJ, Tsang TM, Teahan O, Zhou S, Califano JA, Jeoung NH, Harris RA and Verma A. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem. 2008; 283(33):22700-22708.
25. Grassian AR, Metallo CM, Coloff JL, Stephanopoulos G and Brugge JS. Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. Genes Dev. 2011; 25(16):1716-1733.
26. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM and Stewart DJ. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28(30):4609-4615.
27. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M and Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000; 275(1):223-228.
28. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhausl W and Furnsinn C. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes. 2004; 53(4):1052-1059.
29. Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf). 2009; 196(1):65-80.
30. Vakana E and Platanias LC. AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications. Oncotarget. 2011; 2(12):1322-1328.
31. Bodmer M, Meier C, Krahenbuhl S, Jick SS and Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010; 33(6):1304-1308.
32. Bowker SL, Majumdar SR, Veugelers P and Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29(2):254-258.
33. Vitale-Cross L, Molinolo AA, Martin D, Younis RH, Maruyama T, Patel V, Chen W, Schneider A and Gutkind JS. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prev Res (Phila). 2012; 5(4):562-573.
34. Sikka A, Kaur M, Agarwal C, Deep G and Agarwal R. Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. Cell Cycle. 2012; 11(7):1374-1382.
35. Del Barco S, Vazquez-Martin A, Cufi S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B and Menendez JA. Metformin: multi-faceted protection against cancer. Oncotarget. 2011; 2(12):896-917.
36. Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, Martin-Castillo B and Menendez JA. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget. 2012; 3(4):395-398.
37. Cufi S, Corominas-Faja B, Lopez-Bonet E, Bonavia R, Pernas S, Lopez IA, Dorca J, Martinez S, Lopez NB, Fernandez SD, Cuyas E, Visa J, Rodriguez-Gallego E, Quirantes-Pine R, Segura-Carretero A, Joven J, et al. Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. Oncotarget. 2013; 4(9):1484-1495.
38. Marignac VM, Smith S, Toban N, Bazile M and Aloyz R. Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming. Oncotarget. 2013.
39. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ and Hung MC. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell. 2008; 13(5):385-393.
40. Buller CL, Loberg RD, Fan MH, Zhu Q, Park JL, Vesely E, Inoki K, Guan KL and Brosius FC, 3rd. A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Am J Physiol Cell Physiol. 2008; 295(3):C836-843.
41. Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K and Eucker J. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res. 2012; 32(5):1627-1637.
42. Apontes P, Leontieva OV, Demidenko ZN, Li F and Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget. 2011; 2(3):222-233.
43. Meusser B, Hirsch C, Jarosch E and Sommer T. ERAD: the long road to destruction. Nat Cell Biol. 2005; 7(8):766-772.
44. Le Roy C and Wrana JL. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol. 2005; 6(2):112-126.
45. Thrower JS, Hoffman L, Rechsteiner M and Pickart CM. Recognition of the polyubiquitin proteolytic signal. EMBO J. 2000; 19(1):94-102.
46. Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore PP and Dikic I. Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol. 2003; 5(5):461-466.
47. Ettenberg SA, Magnifico A, Cuello M, Nau MM, Rubinstein YR, Yarden Y, Weissman AM and Lipkowitz S. Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex. J Biol Chem. 2001; 276(29):27677-27684.
48. Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE and Madshus IH. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol. 2002; 156(5):843-854.
49. Xi H, Barredo JC, Merchan JR and Lampidis TJ. Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CaMKKbeta leading to autophagy. Biochem Pharmacol. 2013; 85(10):1463-1477.
50. Terai K, Hiramoto Y, Masaki M, Sugiyama S, Kuroda T, Hori M, Kawase I and Hirota H. AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. Mol Cell Biol. 2005; 25(21):9554-9575.
51. Dong Y, Zhang M, Liang B, Xie Z, Zhao Z, Asfa S, Choi HC and Zou MH. Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. Circulation. 2010; 121(6):792-803.
52. Jung JH, Lee JO, Kim JH, Lee SK, You GY, Park SH, Park JM, Kim EK, Suh PG, An JK and Kim HS. Quercetin suppresses HeLa cell viability via AMPK-induced HSP70 and EGFR down-regulation. J Cell Physiol. 2010; 223(2):408-414.
53. Chou TC and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55.
54. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, Storkel S, Schumacher KM, von Heydebreck A, Celik I and O'Byrne KJ. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012; 13(1):33-42.
55. Nardo G, Favaro E, Curtarello M, Moserle L, Zulato E, Persano L, Rossi E, Esposito G, Crescenzi M, Casanovas O, Sattler U, Mueller-Klieser W, Biesalski B, Thews O, Canese R, Iorio E, et al. Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization. Cancer Res. 2011; 71(12):4214-4225.